Chief Scientific Officer · AGIOS PHARMACEUTICALS, INC. (AGIO)

Scott Biller

A named executive officer of AGIOS PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$3,098,054

Salary $446,573Stock awards $641,025

FY2017: $2,301,877

4th of 5 named executive officers at Agios Pharmaceuticals by FY2018 total.

5 named officers on file for AGIOS PHARMACEUTICALS, FY2018

Scott Biller’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • AGIO’s disclosed peer group of 14 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how AGIOS PHARMACEUTICALS’s whole pay program stands against its peers

  • AGIOS PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AGIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 18, 2019 (DEF 14A).

Free

Get Scott Biller’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Scott Biller compensation by year

AGIOS PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as AGIOS PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$416,890$429,397$446,573
Bonus$0$0$0
Stock awards$0$0$641,025
Option awards$1,145,987$1,639,353$1,746,517
Non-equity incentive$166,760$223,287$251,198
Pension and deferred compensation$0$0$0
All other$10,221$9,840$12,741
Total$1,739,858$2,301,877$3,098,054

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AGIOS PHARMACEUTICALS, INC. DEF 14A filed April 18, 2019, accession 0001193125-19-110870, and prior-year filings. Open the filing on EDGAR.

How this page was built: the AGIOS PHARMACEUTICALS, INC. filed document, accession 0001193125-19-110870. Every figure is read from that document and cited to the page and table it appears in. Filed April 18, 2019.

$1.7M
$2.3M
$3.1M
FY16
FY17
FY18
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,000$477,500—
RSU5,500$262,625—
PSU5,167$246,724—
Option17,880—$77.70
Option1,886—$39.76
Option13,888—$50.40
Option40,000—$58.86

Per the Outstanding Equity Awards at Fiscal Year-End table in AGIOS PHARMACEUTICALS, INC.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

AGIOS PHARMACEUTICALS’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
David SchenkeinPresident and Chief Executive Officer$8,199,324
Andrew HirschChief Financial Officer and Head of Corporate Development$3,136,858
Christopher BowdenChief Medical Officer$3,128,730
Scott Biller · this pageChief Scientific Officer$3,098,054
Steve HoerterChief Commercial Officer$3,096,728

The full AGIOS PHARMACEUTICALS compensation record

free company brief

This page is one person within AGIOS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AGIOS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Scott Biller's compensation dossier · One-time report. No refunds.